FDA Brushes Aside Scientific Data In Deregulating Chemical Abortion Pills

According to scientific medical studies, Joe Biden’s Food and Drug Administration (FDA) used incomplete data to conclude that it should deregulate chemical abortion pills.

The FDA determined that women should obtain abortion pills without an in-person consultation with a doctor, even though concerns for their health resulting from the procedure were identified.

The deregulation relied on the FDA’s Adverse Event Reporting System, designed to assemble and analyze reports of adverse side effects of drugs like the abortion pill medication mifepristone. However, the database does not require emergency room providers to report adverse incidents. Although some studies show that thousands of women need emergency treatment due to taking mifepristone, those cases are not necessarily reported at all in the FDA data.

Instead, the FDA system relies on reports provided by the manufacturers of the abortion drugs based on information obtained from doctors providing prescriptions. A new study shows that the FDA only reports some of the required data. During the study period, less than half of the adverse effects reported by Planned Parenthood were made part of the FDA database.

Dr. James Studnicki is a medical expert who worked as a professor at Johns Hopkins University and said that the FDA’s reported data is significantly less than the actual number of adverse effects. He said that the FDA is “pretending to look” for adverse effects and does not show that it is concerned about whether its information is accurate or not.

Studnicki said that manufacturers have provided a “distorted view of reality” through politics and controlling what is considered actual science. He added that the FDA has been compliant in the process.

Democratic legislators have aggressively sought to deregulate abortion pills as many states have enacted new legislation designed to challenge the Supreme Court ruling in Roe v. Wade. More than 70 Democrats signed off as sponsors on a proposed bill providing widespread, easy access to chemical abortion drugs in August.

The FDA changed its rules to exclude all adverse effects other than deaths reported to the database this year.